Online inquiry

IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ391MR)

This product GTTS-WQ391MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TYRP1 gene. The antibody can be applied in Malignant melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000550.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7306
UniProt ID P17643
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ391MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13415MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ11382MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ5934MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ6062MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ9220MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ10882MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ4489MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ15866MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW